Confirmed response rate 35% (11/31), across all tumor types and patient cohorts treated with 1 mg priming dose, including three confirmed, complete responses 32% (6/19) confirmed response rate in ...

Harpoon Therapeutics (HARP) has been making great progress in being able to advance its pipeline, that's because it has done well in advancing its drug HPN328 for the treatment of patients with small ...

Merck is making another play to expand its oncology pipeline through acquisition, announcing Jan. 8 it will add Harpoon Therapeutics Inc. for $23 per share in cash. According to the buyer, the total ...

Expanding its oncology pipeline, Merck completed its acquisition of Harpoon Therapeutics Inc. As of March 11, Harpoon is a wholly owned subsidiary of Rahway-based Merck and its stock will no longer ...